CALGARY, AB , April 29, 2022 /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor. Mr. Nyquvest has extensive capital markets experience, with over 40 years involvement in [...]
Calgary, AB – April 21, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that Marilyn Loewen Mauritz has resigned as a member of the UI Board of Directors to pursue other opportunities. The Board of Directors would like to thank Marilyn for [...]
Calgary, AB – April 7, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has temporarily closed the Kelburn Recovery Centre (“Kelburn”) due to an on-site flooding issue. Kelburn is UI’s addiction treatment site operating near Winnipeg, Manitoba, and which experienced [...]
Calgary, AB – April 5, 2022 – Universal Ibogaine Inc. (TSXV:IBO and OTCQB: IBOGF and FSE: JC4) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares have been approved for trading [...]
Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m. EDT Calgary, Canada - March 24, 2022 -- [Universal Ibogaine] [TSXV:IBO and OTCQB:IBOGF], a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, announced [...]
Calgary, Alberta – March 23, 2022 – Universal Ibogaine Inc. (TSXV:IBO and OTCQB: IBOGF) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce the key strategic addition of Julie Dumouchel as Director of Clinical Trials. [...]
Calgary, AB – February 28, 2022 – Universal Ibogaine Inc. (TSXV:IBO and OTCQB: IBOGF) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares have been approved for trading on the OTCQB [...]
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
© All rights reserved. • Universal Ibogaine Inc.
